文献速递主动脉疾病

BeGraft覆膜支架作为桥接支架用于开窗式主动脉腔内修复术的中期结局

Midterm Outcomes of BeGraft Stent Grafts Used as Bridging Stents in Fenestrated Endovascular Aortic Aneurysm Repair.
PubMed 文献 · J Endovasc Ther · 2022-04-26

本研究纳入2015年11月至2016年9月连续接受开窗式主动脉腔内修复术(fEVAR)并使用BeGraft外周覆膜支架的39例患者(38例男性),共植入101枚第二代BeGraft支架。中位随访33个月(IQ25 17-IQ75 36),桥接支架1年和2年通畅率分别为98%和97%,免于二次手术率为96%(97/101),所有事件均发生于肾动脉支架。

要点

  • 桥接支架1年通畅率98%,2年通畅率97%。
  • 免于二次手术率为96%(97/101)。
  • 所有事件均发生于肾动脉植入的支架。

核心结论

  • 早期良好结局在较长期随访中得到证实,需要警惕性监测。

研究设计与样本

  • 纳入2015年11月至2016年9月连续接受fEVAR并使用当前BeGraft外周覆膜支架的患者,共39例(38例男性),植入101枚第二代BeGraft支架。

主要发现

  • 中位动脉瘤直径为60 mm(54.5-67.0 mm)。
  • 动脉瘤类型:近肾和肾旁19/39(48.1%),4型胸腹主动脉瘤(TAAA)3/39(7.7%),1、2、3型TAAA 7/39(17.8%),5型TAAA 4/39(10.2%),既往EVAR术后I型内漏6/39(15.4%)。
  • 支架植入部位:肠系膜动脉55枚(腹腔干22枚、肠系膜上动脉31枚、肝或脾动脉2枚),肾动脉46枚(右24枚、左22枚)。
  • 肾动脉直径5、6、7、8 mm分别见于9、7、26、4例患者;肠系膜动脉均使用9和10 mm直径装置。
  • 中位随访33个月(IQ25 17-IQ75 36),11例(28%)死于非动脉瘤相关原因。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Fenestrated endovascular aneurysm repair (fEVAR) is established for the treatment of juxtarenal, pararenal, and thoracoabdominal aortic aneurysms (TAAAs). Bridging stents are used to connect the main body of the stent graft to the aortic branch vessels. Complications related to the bridging stents compromise the durability of the repair and require urgent re-intervention. Here we present the midterm results of the BeGraft stent graft system used for fEVAR. MATERIALS AND METHOD: All consecutive patients treated with fEVAR and the current BeGraft Peripheral Stent Graft between November 2015 and September 2016 were included. RESULTS: Thirty-nine consecutive patients (38 men) were enrolled and 101 BeGraft second-generation stent grafts were implanted. The median aneurysm diameter was 60 mm (54.5-67.0 mm). Aneurysms were juxtarenal and pararenal (19/39, 48.1%), type 4 TAAA (3/39, 7.7%), type 1, 2, and 3 TAAA (7/39, 17.8%), type 5 TAAA (4/39, 10.2%), and 15.4% (6/39) had a type I endoleak following a previous EVAR. Fifty-five BeGrafts were implanted in mesenteric arteries (22 in coeliac trunks, 31 in the superior mesenteric artery, and 2 in a hepatic or splenic artery) and 46 into renal arteries (24 right and 22 left). The renal artery diameters were 5, 6, 7, and 8 mm in 9, 7, 26, and 4 patients, respectively. Mesenteric arteries were exclusively stented with 9 and 10 mm diameter devices. The median follow-up was 33 months (IQ25 17-IQ75 36). During follow-up, 11 patients died (28%) from non-aneurysm-related causes. The overall patency rates for bridging stents were 98% and 97% at 1 and 2 years, respectively, with a freedom from secondary procedure rate on BeGraft stent grafts of 96% (97/101). All events occurred on stents implanted in renal arteries. CONCLUSION: Early favorable outcomes are confirmed during longer term follow-up. Vigilant surveillance is required.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Clough RE, Spear R, Mougin J, et al. Midterm Outcomes of BeGraft Stent Grafts Used as Bridging Stents in Fenestrated Endovascular Aortic Aneurysm Repair. J Endovasc Ther. 2022. PMID: 35471131. doi:10.1177/15266028221091894

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。